Previous 10 | Next 10 |
Amryt Pharma press release ( NASDAQ: AMYT ): Q2 GAAP EPS of -$0.02 beats by $0.04 . Revenue of $68.54M (+9.2% Y/Y) beats by $4.28M . Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underwa...
Amryt Reports Record Q 2 2022 Results 9.2 % YoY revenue growth in Q 2 to $ 68.5M 35.3 % YoY revenue growth in Q 2 excluding impact of a sporadic LATAM ...
DUBLIN, Ireland, and Boston MA, July 21 , 202 2 , Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's ( NASDAQ: AMYT ) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the T reatment of C arcinoid S y ndrome DUBLIN, Ireland, and Boston MA , J uly 14 , 2022 , Amryt (Nasdaq: AMYT), a global, com...
Amryt Presents New Analys e s from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch triterpenes) on accelerated wound healing, data on procedural pain and dressing change frequency, ...
DUBLIN, Ireland, and Boston MA, July 1 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to ...
Amryt Pharma (NASDAQ:AMYT) appoints Dr Tracy Cunningham as Chief Medical officer with immediate effect. Dr Cunningham joined the company in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the company portfolio. Prior to thi...
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27 , 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel ...
Amryt (NASDAQ:AMYT) will file a Formal Dispute Resolution Request to the U.S. FDA in response to a Complete Response Letter received in February for Oleogel-S10 (Filsuvez). Oleogel-S10 is under investigation for Dystrophic and Junctional Epidermolysis Bullosa (EB), a rare, genetic s...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...